Compare Twist Bioscience Corp (TWST) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Veritone Inc — how do they compare? Twist Bioscience Corp trades at $124.01 (market cap $7.72B), while Veritone Inc trades at $1.52 (market cap $138.04M). The key difference: Twist Bioscience Corp is far larger — about 55.9× Veritone Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals.
| TWST | VERI | |
|---|---|---|
Market Cap | $7.72B | $138.04M |
Sector | Health | Technology |
52-Week High | $124.88 | $8.39 |
52-Week Low | $24.16 | $1.00 |
Enterprise Value | $7.65B | $170.07M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $123.76, down 0.9% on the day, with a bullish technical signal from moving averages but bearish oscillators. Revenue growth is strong, with 2025 revenue at $376.57 million, though the company remains unprofitable with a net income margin of -31.66%. Recent news highlights an upsized $300 million public offering and an analyst upgrade, contributing to positive sentiment.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, negative cash flow, and high valuation ratios pose significant risks. Investors should weigh the growth trajectory against the path to profitability and cash burn concerns.
Veritone (VERI) trades at $1.46, up 1.39% today, with a bullish technical signal from moving averages despite overbought RSI readings. The company reported a net loss of $111.73M on $92.19M revenue in 2025, with negative profit margins and ROE. Recent news highlights partnerships in AI solutions, but a securities class action lawsuit deadline passed in July 2026.
Outlook remains challenged by persistent losses and high cash burn, offset by analyst optimism with 46% buy ratings. Key risks include the class action, profitability timeline, and competitive AI market. The stock's low price near support levels suggests high volatility potential amid mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
